Mylan must still answer questions on EpiPen, Sen. Grassley says

Share it

img-ambulance-company-to-stop-using-epipens-because-of-high-cost

There needs to be more transparency in drug pricing — including looking at the middlemen — but when it comes to the controversy about Mylan’s pricing of its EpiPen, the company still has a lot of questions to answer

 

Continue Reading Article

See more news